Amino Acid, Peptide, or Protein – Page 5

Zenas BioPharma Shares Plummet After Phase 3 INDIGO Trial for Obexelimab in IgG4-Related Disease Meets Endpoint but Falls Short of Expectations

4 weeks ago talkbio0Tagged Amgen Uplizna, IgG4-Related Disease, Obexelimab, Phase 3 INDIGO, plunge, Zenas BioPharma

Zenas BioPharma; obexelimab; Phase 3 INDIGO; IgG4-related disease; share plunge; Amgen Uplizna

Aktis Oncology Targets $181M-$209M in First Biotech IPO of 2026

4 weeks ago talkbio0Tagged Aktis, IPO, methionine, Neoplasms, Radiopharmaceuticals

Aktis Oncology; IPO; biotech; radiopharmaceutical; 2026; $181M; $200M

Spotlight On: Five key oncology stories to watch in 2026

4 weeks ago talkbio0Tagged 2026, Antibody-Drug Conjugates, cancer research trends, CAR-T, Cell Therapy, Liquid Biopsy, Lymphocytes, Tumor-Infiltrating, mRNA cancer, Neoplasms, oncology decisions, precision oncology, Radiopharmaceuticals, T-Cell Receptor, United States Food and Drug Administration, Vaccines

oncology 2026; cancer research trends; FDA oncology decisions 2026; antibody-drug conjugates; radiopharmaceuticals; liquid biopsy; mRNA cancer vaccines; AI in oncology; cell therapies CAR-T TIL TCR; precision oncology

ScinoPharm Taiwan Secures Historic U.S. FDA Approval for Glatiramer Acetate Injection to Treat Multiple Sclerosis

4 weeks ago talkbio0Tagged Approved, Complex, glatiramer acetate, Multiple Sclerosis, ScinoPharm, Taiwan, United States Food and Drug Administration

ScinoPharm; FDA Approval; Glatiramer Acetate; Multiple Sclerosis; Taiwan; Complex Generic

Ultragenyx and Mereo BioPharma Stocks Crash After Late-Stage Setrusumab Trials Fail in Osteogenesis Imperfecta

4 weeks ago talkbio0Tagged Bone Density, Clinical trial failure, Mereo BioPharma, Osteogenesis Imperfecta, setrusumab, Stock Crash, Ultragenyx

Ultragenyx; Mereo BioPharma; setrusumab; osteogenesis imperfecta; clinical trial failure; stock crash; bone mineral density

Lunit SCOPE AI Achieves High Concordance in HER2 Assessment for Biliary Tract Cancer

4 weeks ago talkbio0Tagged Agreement, Biliary Tract Cancer, erbB-2 Receptor, Lunit SCOPE, Medical pathologist, Pathology

Lunit SCOPE; HER2; biliary tract cancer; AI pathology; concordance; pathologists

Patient Dies from Thrombotic Stroke in Pfizer’s Hympavzi Hemophilia Trial After Minor Surgery

1 month ago talkbio0Tagged Clinical Trials, Hemophilia A, HYMPAVZI, marstacimab, Patient Death, Pfizer, Thrombotic Stroke

Pfizer; Hympavzi; marstacimab; hemophilia; thrombotic stroke; patient death; clinical trial

Neurocrine’s VMAT2 Inhibitor Valbenazine Fails in Phase 3 Trial for Dyskinetic Cerebral Palsy

1 month ago talkbio0Tagged Athetoid cerebral palsy, Chorea, KINECT-DCP, Neurocrine, Phase 3 trial, valbenazine, VMAT2 Inhibitor

Neurocrine; valbenazine; VMAT2 inhibitor; dyskinetic cerebral palsy; KINECT-DCP; Phase 3 trial; chorea

Novo Nordisk Wins FDA Approval for First Oral GLP-1 Wegovy Pill in Obesity Treatment

1 month ago talkbio0Tagged Approved, Glucagon-Like Peptide 1, Novo Nordisk, Obesity, oral semaglutide, United States Food and Drug Administration, Wegovy pill

Novo Nordisk; Wegovy pill; FDA approval; oral semaglutide; obesity treatment; GLP-1

White House unveils nine new “most-favored-nation” drug pricing deals

1 month ago talkbio0Tagged drug price, eli lilly, Health Policy, MFN, Most-Favored-Nation, Nordisk, Ozempic, pharmaceutical manufacturers, prescription drug costs, Trump administration, U.S., Wegovy, White House

most-favored-nation pricing; MFN; drug pricing; White House; Trump administration; pharmaceutical manufacturers; Ozempic; Wegovy; Eli Lilly; Novo Nordisk; prescription drug costs; US healthcare policy